Japan has granted the world's first regulatory approval for the commercial sale of iPS cell-based medical treatments. This historic milestone, supported by extensive research in PubMed, transitions induced pluripotent stem cell technology from the laboratory to the clinic, positioning Japan as the global leader in regenerative medicine.
Jessy·
Japan has granted the world's first regulatory approval for a medical product derived from induced pluripotent stem cells (iPSCs), a technology that won the Nobel Prize in 2012. This milestone enables the mass production of standardized 'off-the-shelf' cell therapies, starting with cancer treatments. Analysts expect this move to trigger a global surge in regenerative medicine investment and set new regulatory standards for the US and Europe.
Williams·
Japan has granted the first-ever regulatory approval for a medical product based on induced pluripotent stem cells (iPSCs), a breakthrough technology pioneered 20 years ago. This milestone marks the shift of regenerative medicine from the lab to commercial healthcare, offering new hope for spinal cord and nerve repair.
Williams·